Predicting outcomes for patients with acute myeloid leukemia (AML) on the basis of pretreatment predictors has been the cornerstone of management. Posttreatment prognostic factors are increasingly being evaluated. METHODS: Among 280 younger patients who were treated with intermediate-dose cytarabine (total 5 g/m 2 ) and idarubicin-based induction chemotherapy and achieved remission, 186 were assessed for minimal residual disease (MRD) with an 8-color multiparameter flow cytometry panel performed on bone marrow specimens with a sensitivity of 0.1% or higher. RESULTS: One hundred sixty-six patients had samples available 1 to 2 months after induction at the time of complete remission (CR), and 79% became negative for MRD, with an MRDnegative status associated with an improvement in relapse-free survival (RFS; P 5.0002) and overall survival (OS; P 5.0002). One hundred sixteen were evaluated for their MRD status during consolidation, and 86% were negative, with an MRD-negative status associated with a significant improvement in RFS (P <.0001) and OS (P <.0001). Sixty-nine patients were evaluated for their MRD status after completion of all therapy, and 84% were negative, with an MRD-negative status associated with an improvement in RFS (P <.0001) and OS (P <.0001). In a multivariate analysis including age, cytogenetics, response (CR vs CR with incomplete platelet recovery/incomplete blood count recovery), and MRD, achieving an MRD-negative status was the most important independent predictor of RFS and OS at response (P 5.008 and P 5.0008, respectively), during consolidation (P <.0001 for both), and at the completion of therapy (P <.0001 and P 5.002, respectively). CONCLUSIONS: Achieving an MRD-negative status according to multiparameter flow cytometry is associated with a highly significant improvement in the outcomes of younger patients with AML receiving cytosine arabinoside plus idarubicin-based induction and consolidation regimens. Cancer 2017;123:426-35.
INTRODUCTION
Predicting the outcomes of therapy for patients with acute myeloid leukemia (AML) treated with cytotoxic chemotherapy regimens has been an important aspect of therapeutic decision making, particularly with respect to the selection of postremission therapy. 1 This prediction has been based mainly on pretreatment factors related to a patient's ability to tolerate intensive therapy as well as disease-related variables such as the karyotype, molecular features, and other biological features hitherto determined to be associated with resistance to the standard cytarabine and anthracycline regimens. [2] [3] [4] Although a response to therapy and particularly the achievement of morphologic complete remission (CR) have been clearly associated with better outcomes, few other measures of leukemic cell drug sensitivity, such as early blast clearance and an early marrow response, have been consistently used to determine the likely durability of a response. [5] [6] [7] This is in contrast to studies in pediatric acute lymphoblastic leukemia (ALL), in which early measures of drug sensitivity, such as early responses to chemotherapy, have been commonly used to determine the need for intensification of therapy. 8, 9 This may be partly due to the higher likelihood of inherent leukemia resistance to cytotoxic agents and the lower probability that intensification will be well tolerated and improve the outcomes for adults with AML. On the other hand, with the high response rates achieved after intensive chemotherapy regimens, pediatric investigators have begun to increasingly rely on markers of minimal residual disease (MRD) for the selection of patients with ALL and AML for further intensification. 10, 11 In the adult population, it can be argued that an MRD assessment will be more valuable for younger patients, who can tolerate more intensive induction therapy, have a higher likelihood of achieving CR, and are more likely to be candidates for allogeneic stem cell transplantation.
The recent availability of sensitive assays that can detect residual, submicroscopic leukemia on the basis of leukemia-specific features such as aberrant immunophenotypes and abnormal molecular markers and the prospect of the future availability of novel agents that are more diseasespecific and potent have rekindled interest in MRD assessment for adult AML. [12] [13] [14] [15] Although prior studies have established the value of MRD assessment for adult patients with AML treated with cytotoxic regimens, its value in prognostication and postremission therapeutic decision making and the best assay for detecting it continue to be debated. 12 Here we report data for adult patients with AML treated at our institution with intensive chemotherapy regimens, and we examine the prognostic value of MRD detection with multiparameter flow cytometry.
MATERIALS AND METHODS

Patients
From April 2007 to June 2015, 318 patients with newly diagnosed AML were treated with 1 of 4 regimens containing an intermediate dose (total dose 5 g/m 2 ) of cytarabine in addition to idarubicin for induction and consolidation courses. All patients either were younger than 65 years or, if older, had to have favorable cytogenetics/molecular features (European LeukemiaNet) and be deemed fit to receive chemotherapy. Among these patients, 280 (88%) achieved CR, complete remission with incomplete platelet recovery (CRp), or complete remission with incomplete blood count recovery (CRi); these were defined according to the revised International Working Group criteria. 16 Flow MRD analysis was available for 186 patients (58%), and they were the subjects of this study. Ninety-four patients, including 62 (66%) with core binding factor leukemia (who were typically monitored with molecular testing alone), did not have flow MRD analysis available. Table 1 summarizes the characteristics of these patients. All patients were treated in clinical trials approved by the institutional review board of The University of Texas MD Anderson Cancer Center, and written informed consent was obtained from all patients before entry into the studies in accordance with the Declaration of Helsinki. The details of the various treatment regimens have been previously published. 17, 18 Briefly, in all regimens, the induction course contained idarubicin (total dose, 12-30 mg/m 2 ) as well as intermediate-dose cytarabine (total dose, 5-10 g/m 2 ). In the fludarabine, idarubicin, and cytarabine (FIA) regimen, fludarabine (30 mg/m 2 daily for 5 days) was given in addition to idarubicin and cytarabine (IA). Similarly, in the clofarabine, idarubicin, and cytarabine (CIA) and cladribine, idarubicin, and cytarabine (CLIA) regimens, clofarabine (15 mg/m 2 daily for 5 days) and cladribine (5 mg/m 2 daily for 5 days) were administered in addition to IA. In the fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-Ida) regimen, fludarabine (30 mg/m 2 daily for 5 days) and granulocyte colony-stimulating factor (5 mg/kg) were included in addition to IA. Patient outcomes in terms of survival and relapse-free survival (RFS) were similar for the FIA, CIA, and CLIA regimens; the FLAG-Ida regimen was used almost entirely for patients with favorable-risk cytogenetics and, as such, was expected to be associated with better outcomes. In all the aforementioned regimens, consolidation consisted of up to 6 cycles of attenuated doses of the same agents. A summary of the treatment regimens is shown in Supporting Table 1 (see online supporting information).
Response Definitions
The response assessment was based on the revised criteria defined by the International Working Group for AML. 16 To achieve CR, patients needed to have less than 5% blasts according to a morphological assessment of a bone marrow specimen together with an absolute neutrophil count 1000/mL and a platelet count 100,000/mL in the peripheral blood with no evidence of extramedullary disease. The definition of CRp met these criteria except that the platelet count was <100,000/mL, whereas the definition of CRi met these criteria except that the absolute neutrophil count was <1000/mL or the platelet count was <100,000/mL.
16
MRD Analysis by Flow Cytometry
The MRD assessment by multiparameter flow cytometry was performed on whole bone marrow specimens with a standard stain-lyse-wash procedure with ammonium chloride lysis. Cells (1 3 10 6 ) were stained per analysis tube, and data were acquired for at least 2 3 10 5 cells when the specimen's quality permitted that. Data on standardized 7-to 8-color staining combinations were acquired on FACSCanto II cytometers with FACSDiva software (BD Biosciences) and were analyzed with FCS Express (De Novo Software). Several different tube configurations were used through the course of the study, all with staining for CD2, CD4, CD5, CD7, CD13, CD14, CD15, CD19, CD33, CD34, CD38, CD45, CD56, CD64, CD117, CD123, and HLA-DR. All tubes included CD34 and CD45. Both CD34 1 cells and a broader gate including CD45 dim mononuclear cells and monocytes were analyzed in parallel for all cases.
MRD was identified in comparison with the known patterns of antigen expression by normal maturing myeloid precursors and monocytes as previously described. 19, 20 Specimens for comparison included normal and regenerating marrows. MRD was quantitated as a percentage of total leukocytes after the exclusion of most red blood cell precursors by forward scatter. A distinct cluster of at least 20 cells showing altered expression of at least 2 antigens was regarded as an aberrant population; this yielded an optimal sensitivity of 1 in 10 4 cells or 0.01%. For cases with significant phenotypic overlap between leukemic blasts and normal myeloid precursors or monocytes, the sensitivity was lower, with an average sensitivity for all cases estimated to be 0.1%. All specimens with positive results were included for an analysis of clinical outcomes. Specimens with negative results but with suboptimal cell counts were excluded. When available, the phenotypic profiles of pretreatment blasts were compared with those of specimens submitted for MRD testing.
Statistical Analysis
Patient characteristics were summarized with frequencies and percentages for categorical variables and with medians and ranges for continuous variables. Overall survival (OS) was defined as the time interval from the treatment initiation date to the date of death due to any cause. Patients who were alive were censored at the date of allogeneic stem cell transplantation or last follow-up. RFS was defined as the time interval from the response date to the date of disease relapse or death due to any cause, whichever occurred first. Patients remaining alive and in continued remission were censored at the date of transplantation if they underwent an allogeneic stem cell transplant or at the date of last follow-up. The probabilities of OS and RFS were estimated with the Kaplan-Meier method. 21 Cox proportional hazards regression models were fit to assess the association between OS or RFS and patient characteristics. 22 We used the method described by Gooley et al 23 to estimate the cumulative incidence of relapse, with death considered as a competing event. 23 All statistical analyses were conducted with SAS and S-Plus. Table 1 summarizes the patient characteristics. All patients were diagnosed as having AML according to World Health Organization criteria (20% blasts in the pretreatment bone marrow or peripheral blood). 1 The median age of the cohort of 186 patients was 51 years (range, 17-77 years); only 6 patients (3%) were older than 65 years, and all had favorable disease (European LeukemiaNet). 4 The median white blood count at diagnosis was 4.7 3 10 9 /L (range, 0.5-103 3 10 9 /L). The cytogenetics were considered favorable-risk for 34 (18%), intermediate-risk for 115 (62%), and adverse for 27 (15%), and the data were not available for 10 patients (5%). One hundred seventy-four (94%) achieved CR, with 11 (6%) achieving CRp and 1 (<1%) achieving CRi. Among these patients, 174 (94%) achieved their response after 1 course of induction, and 12 (6%) required at least 2 courses. Sixty-seven patients (36%) underwent an allogeneic stem cell transplant during their first CR. Among the patients who underwent transplantation during their first CR, 13 relapsed, and 45 were surviving in CR (9 died in CR after transplantation). The last MRD evaluation was positive for 10 and negative for 56 (and not available for 1) among the transplant patients, and there was no difference in survival after transplantation between the 2 groups (P 5 .8).
RESULTS
Patient Characteristics and Disposition
The characteristics of the 94 patients seen and treated during the same period who were not included in the study because of the lack of availability of MRD data are also shown in Table 1 . The majority (66%) had favorable-risk cytogenetics and, as such, were monitored by reverse transcription-polymerase chain reaction analysis of the relevant fusion transcripts and not by flow cytometry. Similarly, 61 members of this cohort (65%) were treated with the FLAG-Ida regimen, which was specifically designed for this subset.
Among the 186 patients who achieved CR/CRp/ CRi and had an MRD analysis, 166 had samples available 1 to 2 months after induction at the time of achieving CR, and 79% became MRD-negative (Fig. 1) . One hundred sixteen were evaluated for their MRD status during consolidation (after a median of 2 cycles of consolidation; range, 1-5), and 86% were negative. Sixty-nine patients were evaluated for their MRD status after the completion of all therapy, and 84% were negative (Fig. 1) .
Predictors of Outcome
We evaluated potential predictors of RFS and OS, including known covariates such as the patient's age, white blood cell count at presentation, cytogenetics, and MRD, at various time points. In a univariate analysis, the cytogenetics (favorable vs other), the percentage of bone marrow blasts at diagnosis, the type of response (CR vs CRi/CRp), and the type of therapy (FLAG-Ida vs CLIA/CIA/FIA) as well as the achievement of a negative MRD status at all 3 time points were factors predictive of a better outcome for RFS and OS (Tables 2 and 3 ). The type of therapy was confounded by cytogenetics because the FLAG-Ida regimen was specifically used for patients with favorable-risk cytogenetics (Supporting Table 2 [see online supporting information]).
The achievement of an MRD-negative state at all time points investigated (at the time of achieving a response [1-2 months after the start of therapy], during consolidation [3-7 months after the start of therapy], and after the completion of all therapy [8 months after the start of therapy]) was associated with a significant improvement in RFS and OS (Fig. 2) . We also examined the prognostic value of achieving an MRD-negative state in the subgroup of patients with intermediate-risk cytogenetics. Again, achieving MRD negativity at CR, during consolidation, and after the completion of therapy was associated with significantly better RFS and OS (Supporting Fig. 2 [see online supporting information]). We did not perform this analysis for the favorable and adverse cytogenetics subgroups because of the limited numbers of patients in these subsets (34 and 27, respectively).
Cumulative Incidence of Relapse
The cumulative incidence of relapse was estimated with Gooley et al's method 23 and is presented in Figure 3 . There was a significant difference in the incidence of relapse for the MRD-negative and MRD-positive cohorts at the recorded time points (at response, during consolidation, and at the completion of consolidation).
When patients in the intermediate-risk cytogenetic category (n 5 105) were considered, there was also a significant difference in the cumulative incidence of relapse between patients who were MRD-negative and patients who were MRD-positive at the time of achieving a response, during consolidation, and after the completion of therapy (Supporting Fig. 3 [see online supporting information]). Again, this analysis was not performed for the favorable-and poor-risk groups because of their small sample sizes (34 and 27, respectively).
Outcome Prediction by MRD With Respect to Other Covariates
We then examined the value of the MRD status at response, during consolidation, and after the completion of therapy in predicting RFS and OS with respect to other known prognostic covariates. At the time of achieving a response (1-2 months after the start of therapy), data were available for 166 patients. A multivariate analysis a Abbreviations: CI, confidence interval; CIA, clofarabine, idarubicin, and cytarabine; CLIA, cladribine, idarubicin, and cytarabine; CR, complete remission; CRi, complete remission with incomplete blood count recovery; CRp, complete remission with incomplete platelet recovery; FIA, fludarabine, idarubicin, and cytarabine; FLAG, fludarabine, cytarabine, and granulocyte colony-stimulating factor; FLT3, Fms-like tyrosine kinase 3; HR, hazard ratio; ITD, internal tandem duplication; LDH, lactate dehydrogenase; MRD, minimal residual disease; NA, not available; NPM1, nucleophosmin; WBC, white blood cell count. b Not estimable because of no events (ie, relapse or death) in the CLIA group due to the short follow-up. The FLAG regimen was used only for patients with core binding factor leukemia; this confounded the outcomes. including age, cytogenetics (favorable vs other), type of response, and MRD status as covariates demonstrated cytogenetics (P 5 .02) and an MRD-positive status (P 5 .008) as the only significant predictors of RFS (Table  4) . A similar analysis for OS indicated age (P 5 .05), cytogenetics (P 5 .01), and MRD status (P 5 .0008) as the important predictors of OS (Table 5) . A multivariate analysis performed at other time points (during consolidation and after the completion of therapy) showed the MRD status to be the only statistically significant predictor for RFS (P 5 .0001 for both time points) and for OS (P < .0001 and P 5 .002, respectively; Tables 4 and 5 ).
DISCUSSION
Despite significant progress in the treatment of patients with acute leukemia, the majority of patients relapse. 24 Although a subset of relapsed patients can be rescued with allogeneic stem cell transplantation, the vast majority are resistant to their salvage treatments and die of their disease. 25 Therefore, new agents with different mechanisms of action that can overcome this resistance to cytotoxic chemotherapy are needed. Clearly, however, the best strategy for managing relapse is to prevent it.
An assessment of minimal residual leukemia persisting after the initial therapy has been of significant interest for pediatric patients with ALL (and more recently for adults with ALL and AML), although defining the most reliable assay for this purpose remains controversial except for certain subgroups. 12 The utility of polymerase chain reaction-based assays for MRD monitoring in patients with acute promyelocytic leukemia and core binding factor leukemias is well established, and more recent reports have demonstrated the potential importance of MRD monitoring in patients with nucleophosmin (NPM1) mutatations. [26] [27] [28] [29] [30] There are fewer large studies examining the benefit of MRD monitoring by flow cytometry in adult AML, and concerns regarding the standardization and reproducibly of the assays remain. [31] [32] [33] However, the available data suggest that MRD monitoring by any means, imperfect though it may be, can assist in identifying individuals who are destined to relapse. This is of increasing relevance and importance as the potential for the development of novel, less toxic, and more effective agents against residual leukemia populations becomes ever more realistic.
Our data, coming from a relatively large population of younger patients with AML who received a more intensive induction and consolidation regimen and achieved a high CR rate, further demonstrate the significant value of MRD assessment for patients with AML. The more intensive regimens with higher doses of cytarabine used in induction and the continued use of anthracyclines in consolidation are close to the limit of tolerance for cytotoxic chemotherapy in this younger population, and they are akin to the very intensive regimens used in pediatric trials. As such, persisting overt leukemia (primary refractory disease) and even persisting MRD after such therapy can be more closely attributed to the inherent biological resistance of the leukemic cells rather than the inadequacy of therapy, and this clearly selects patients who are no longer benefiting from the cytotoxics. 34 We have previously reported that patients who fail to achieve morphological remission after 1 course of such intensive induction regimens have a dismal prognosis, and very few can be salvaged with an allogeneic stem cell transplant. 35 The data from this report suggest that this observation can be taken a step further, and we can identify the patients more likely to relapse after achieving CR and prevent relapse by selecting novel therapeutic strategies to eradicate MRD and following this with an allogeneic stem cell transplant.
In pediatric leukemia, whose population is more tolerant of cytotoxic agents, MRD assays have been successfully used to select patients for dose intensification. 10, 11 Although in the adult population one can consider persistent MRD to be an indication for allogeneic stem cell transplantation, recent data showing that detectable MRD before an allogeneic stem cell transplant is a reliable predictor of failure suggest that this strategy may not be the best for dealing with persistent MRD after induction and consolidation. 36, 37 Alternative strategies such as monoclonal antibody-based therapies, including antibody-drug conjugates and T-cell-engaging antibodies, and the use of appropriate small molecule inhibitors, such as isocitrate dehydrogenase and Fms-like tyrosine kinase 3 kinase inhibitors, in specific cases may provide us with more effective and less toxic ways to eradicate MRD. Currently, on the basis of precedent, allogeneic stem cell transplantation remains the only time-tested, immunologically driven tool for producing long-term cures in less favorable subsets of AML patients and in patients with relapsed disease. However, with more sensitive and validated assays for MRD and with novel therapeutic strategies, including combinations of antibodies and small molecule inhibitors, we can predict that more and more patients will achieve a long-term cure without the need for an allogeneic stem cell transplant, just as has been the case for patients with acute promyelocytic leukemia, for whom, with the exception of a select few patients suffering relapse, sensitive MRD monitoring and the availability of effective targeted agents have rendered transplantation unnecessary.
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